# Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses

> **NIH NIH R50** · WISTAR INSTITUTE · 2024 · $237,136

## Abstract

Project Summary
The Proteomics and Metabolomics Shared Resource (PMSR) provides a comprehensive set of proteomics and
metabolomics assays to the Wistar Cancer Center, Fox Chase Cancer Center at Temple University, and Sidney
Kimmel Cancer Center at Thomas Jefferson University as a primary goal. Resources of the PMSR are also
available to investigators in other Cancer Centers and academic institutions as a secondary goal. Dr. Tang’s
role as the PMSR Managing Director is to support NCI-funded cancer research projects by providing expert
consultation and state-of-the-art technologies that operate at maximum performance at affordable costs to
cancer investigators and other biomedical researchers. The Managing Director will assist in experimental
design, perform MS data analyses as needed, and assist in the biological interpretation of results. The Managing
Director will also devote substantial effort to optimizing and implementing new methods, update analytical and
data analyses methods, and update instrumentation to ensure each project is performed using state-of-the-art
methodologies. This is critical because instrumentation, software, and analytical strategies continue to evolve
rapidly, and most current and anticipated future projects involve very challenging proteomics and metabolomics
problems. Proteomics projects will include: 1) in-depth, global quantitative comparisons of exosomes,
secretomes, cell lysates, tissues and biological fluids; 2) quantitative comparisons of post-translational
modifications; and 3) LC-MS/MS analysis of isolated protein complexes with and without chemical crosslinking.
Quantitative data will be obtained either using label-free quantitation of integrated MS ion currents, or using
stable isotopes such as SILAC or TMT isobaric tag labeling. Metabolomics projects will include quantifying the
steady state levels of polar metabolites, lipids and fatty acids, and 13C isotope tracer analysis. Representative
specific plans for future development of new analytical approaches include: 1) improving characterization of
protein palmitoylation with identification of specific modification sites; 2) de novo peptide sequencing for
identification of HLA peptides; 3) an alternate approach to ubiquitome enrichment; and 4) absolute quantitation
of gut metabolites. In addition, Dr. Tang will implement additional new or improved methods that are likely to be
needed in future cancer projects. These proteomics and metabolomics analyses will contribute to critical data
required to identify biomolecular targets, as well as generate hypotheses that are vital for the success of the
cancer-related projects described in this application.

## Key facts

- **NIH application ID:** 10910098
- **Project number:** 5R50CA221838-08
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Hsin-Yao Tang
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $237,136
- **Award type:** 5
- **Project period:** 2017-09-20 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10910098

## Citation

> US National Institutes of Health, RePORTER application 10910098, Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses (5R50CA221838-08). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10910098. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*